Contents lists available at ScienceDirect



Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Cyclic glycopeptidomimetics through a versatile sugar-based scaffold

Maria Altamura^a, Elisa Dragoni^{b,e}, Angela Simona Infantino^b, Laura Legnani^c, Steve B. Ludbrook^d, Gloria Menchi^b, Lucio Toma^c, Cristina Nativi^{b,e,*}

^a Menarini Ricerche S.p.A., via dei Sette Santi 1, I-50131 Firenze, Italy

^b Dipartimento di Chimica Organica, Universita' di Firenze, via della Lastruccia, 13-Polo Scientifico e Tecnologico, Sesto F.no, I-50019 Firenze, Italy

^c Dipartimento di Chimica Organica, Universita' di Pavia, via Taramelli 10, I-27100 Pavia, Italy

^d Dept of Screening and Compound Profiling, GlaxoSmithKline R&D, New Frontiers Science Park, Harlow, Essex CM19 5AW, UK

^e CERM, Universita' di Firenze, via Sacconi, 6-Polo Scientifico e Tecnologico, Sesto F.no, I-50019 Firenze, Italy

ARTICLE INFO

Article history: Received 16 February 2009 Revised 31 March 2009 Accepted 3 April 2009 Available online 9 April 2009

Keywords: Glycopeptides Peptidomimetics Sugar aminoacids Tachykinins Integrins

ABSTRACT

Cyclic peptidomimetics are attracting structures to obtain a distinct, bioactive conformation. Even more attractive are sugar-containing cyclic peptidomimetics which present turn structures induced by the pyranose ring when incorporated in cyclic peptides. The use of a new and versatile saccharidic scaffold to achieve sugar-based peptidomimetics is here reported together with the successful synthesis of diastereomerically pure cyclic SAA peptidomimetics **15** and **16**.

© 2009 Elsevier Ltd. All rights reserved.

Low bioavailability, poor stability towards peptidases and rapid excretion displayed by a large number of peptides of therapeutic and biological interest, prompted an intensive search for peptidomimetics.^{1–3} As a matter of fact, peptidomimetics molecules, are expected to have the same therapeutic effects as their peptide counterparts, with the added advantages of metabolic stability and bioavailability.

A possible approach of such peptidomimetics is to replace the peptide, or part of the peptide, by a scaffold that distributes in the space the epitopes. Ideally, an attractive scaffold should easily be available as chiral, enantiomerically pure, building block. It should be highly functionalized to introduce various side chains and its flexibility or rigidity could be modulated. Therefore, the use of sugars as scaffolds in mimetic synthesis is a strategy that has been widely studied and which still draws attention.^{4–6}

Sugar derivatives can be incorporated in the peptide backbone or in the side chains; modification of peptide skeleton by introducing carbohydrate derivatives is documented leading to a real improvement of the properties of the peptides. Moreover, because of the presence of pyranose ring, sugar aminoacids (SAAs) have been found to introduce turn structures when incorporated in linear or cyclic peptides.⁵

* Corresponding author. E-mail address: cristina.nativi@unifit.it (C. Nativi). Cyclization of peptides affords structure of special interest to obtain a distinct, bioactive conformation, and several SAAs have been used as building blocks for peptide scaffolds and conformational restrained peptido-mimetics.^{2,7} Indeed, this approach has been successfully evaluated for biologically active, cyclic RGD peptides³ or cyclic peptides with the β -turn motif of somatostatin, containing tetrapeptide Phe-D-Trp-Lys-Thr.^{2,8}

Consequently, efficient syntheses and availability of suitable saccharidic scaffolds allowing the systematic modification of the amino acids and the carbohydrate residues, as well as the size of the macrocycle, remain a challenging and attracting target to fully exploit the potential of such hybride structure, in the search of new active compounds.

We report herein the use of the α -o-linked glycohomoglutamate **1**, (Scheme 1), easily obtained as distereomerically pure compound by chemo-, regio- and stereoselective cycloaddition between glucal **2** and aspartic acid derivative **3**,⁹ as versatile, multifunctionalized scaffold in the synthesis of cyclic SAA-peptidomimetics **15** and **16** (Scheme 2).

Scaffold **1**, characterized by two orthogonally protected carboxyls, a protected α -amino function and a selectively functionalized monosaccharidic unit, was successfully employed to obtain the monosilyl derivative **4** which, in turn, was oxidized with TEMPO/ BAIB to give the glucuronic derivative **5** (see Scheme 1) in 54% yield. No sulfoxide derivative **6** was observed under these reaction conditions (see Supplementary data).¹⁰ Condensation reactions



Scheme 1. Synthesis of scaffold 5 and structure of cyclo SAA peptidomimetics 15 and 16.

between **5** and **7** as well as between **5** and **8** were performed using standard conditions (see Supplementary data) affording respectively compounds **9** and **10** (Scheme 2). Peptidic chains **7** and **8** as well as SAA derivatives **9** and **10** have been obtained relying on standard solid-phase strategy, using 2-chlorotrityl resin. Removal of the resin, gave linear glycopeptides **11** (62%, over 10 steps) and **12** (25%, over 11 steps) which were treated with trifluoroacetic acid to take off the Boc protecting group quantitatively affording derivatives **13** and **14**, as trifluoroacetic salts. Intramolecular condensation of the latter, and suitable deprotection, gave the cyclo glycopeptides: *cyclo*(SAA**5**-Ala-Phe-Phe-Phe-Ala) **15**, and *cyclo*(SAA**5**-Glu-Ile-Leu-Asp-Val) **16**, (see Supplementary data) which were prepared to be tested as tachykinin NK₂ receptor ligand and integrin (α 4 β 1) inhibitor respectively (Scheme 2).

In a previous paper¹¹ we have shown how insertion of aromatic groups on a suitable sugar derived scaffold can mimic the structure of highly active tachykinin NK_2 antagonists such as the small monocyclic pseudopeptide **17**¹² (Fig. 1).

Indeed, some of the compounds we obtained showed binding affinities at the human tachykinin NK₂ receptor at submicromolar concentrations, while molecular dynamics calculations indicated that the structures of **17** and that of one of the best sugar derived compounds were quite well superimposable. As tachykinin NK₂ antagonists continue to raise interest as potential new drugs for the therapy of gastrointestinal and CNS diseases,¹³ we turned our attention to the synthesis of compounds in which small peptide sequences, containing aromatic aminoacids (Phe) and alanine residues as chiral spacers, are linked to the sugar derived rigid scaffold **5** in order to distribute the aromatic moieties in suitable



Capitalizing on this encouraging result, further work is ongoing in order to increase the biological activity through the modulation of the peptide sequence assisted by molecular dynamics calculations.

It is known that a requisite for a good recognition by NK₂ receptors is the presence of two close aromatic rings in the axial position about the backbone ring.¹⁵ We performed a preliminary modeling study of compound **15** to locate its allowed conformations;¹⁶ the molecule showed a high degree of conformational flexibility and several populated geometries. Among them, two significant conformations show two of the three phenyl rings oriented in the same region of the space, though they do not belong to adjacent aminoacidic residues as in **17**. These conformations, reported in Figure 2, are stabilized by a β -turn motif and support the potential interest in such cyclic glycopeptidic structures.

Integrins are a family of membrane-spanning adhesion receptors composed of non- covalently linked α and β subunits which combine to give a wide amount of heterodimers. In recent years antagonists of very late antigen-4 (VLA4, also known as integrin α 4 β 1) have shown great promise in treating inflammatory disorders.^{17–19} VLA4 recog-



Figure 1. Structure of compound 17.



Figure 2. 3D plot of representative conformations for compound 15.



Scheme 2. Synthesis of open-chain SAA peptides 13 and 14.

nizes polypeptide domains containing the Glu-Ile-Leu-Asp-Val aminoacid sequence whose specificity and efficacy is determined by the contest (flanking residues, conformational presentation, etc.). A number of peptidomimetics have been proposed as anti-VLA4 agents and in this contest the cyclo SAA peptidomimetic **16** was prepared and tested for inhibitory activity against $\alpha 4\beta 1$ integrin by assessing ability to inhibit the adhesion of U937 and Jurkat cells to a VCAM-1 coated surface²⁰ demonstrating a lack of inhibition of these processes up to a concentration of 100 μ M.

In summary, the monosaccharidic scaffold **5**, efficiently obtained as diastereomerically pure compound, was successfully used to synthesize cyclic SAA peptidomimetics. As suggested by molecular calculations, a pentapeptidic sequence should well fit to form macrocyclic structures, therefore biologically engaging compounds **15** and **16** were prepared as single diastereoisomers. *Cyclo*(SAA**5**-Ala-Phe-Phe-Phe-Ala) **15** was tested as tachykinin NK₂ ligand, showing some, although limited, activity which can likely be rationalized on the basis of a correct orientation of its phenyl groups. *Cyclo*(SAA**5**-Glu-Ile-Leu-Asp-Val) **16**, however, did not exhibit activity against $\alpha 4\beta$ 1 integrin. Relying on the versatility and potentials of the scaffold **5** we propose herein, assisted by molecular modeling studies, further work is ongoing to prepare an array of cyclic SAA peptidomimetics containing proper peptidic chains to interact with specific biological targets.²¹

Acknowledgments

We thank Dr. A. Triolo and Dr. E. Libralesso (Menarini Ricerche) for helpful discussions on MS and NMR spectra and Ente Cassa di Risparmio di Firenze for Ph.D. grant of E.D.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bmcl.2009.04.008.

References and notes

- (a) Hanessian, S.; McNaughton-Smith, G.; Lombart, H.-G.; Lubell, W. D. Tetrahedron 1997, 53, 12789; (b) Hanessian, S.; Auzzas, L. Acc. Chem. Res. 2008, 41, 1241. and references cited therein.
- Graf von Roedern, E.; Lohof, E.; Hessler, G.; Hoffmann, M.; Kessler, H. J. Am. Chem. Soc. 1996, 118, 10156.
- For recent reviews see: (a) Gruner, S. A. W.; Locardi, E.; Lohorf, E.; Kessler, H. Chem. Rev. 2002, 102, 491; (b) Schweizer, F. Angew. Chem., Int. Ed. 2002, 41, 231; (c) Cipolla, L.; Peri, F.; La Ferla, B.; Redaelli, C.; Nicotra, F. Curr. Org. Synth. 2005, 2, 153.
- (a) Lohof, E.; Plaker, E.; Mang, C.; Burkhart, F.; Dechantsreiter, M. A.; Haubner, R.; Wester, H. J.; Schwaiger, M.; Holzemann, G.; Goodman, S. L.; Kessler, H. *Angew. Chem., Int. Ed.* **2000**, 39, 2761; (b) Locardi, E.; Stockle, M.; Gruner, S.; Kessler, H. J. Am. Chem. Soc. **2001**, 123, 8189.
- (a) van Well, R. M.; Marinelli, L.; Altona, C.; Erkelens, K.; Siegal, G.; van Raaij, M.; Llamas-Saiz, A. L.; Kessler, H.; Novellino, E.; Lavecchia, A.; van Boom, J. H.; Overhand, M. J. Am. Chem. Soc. 2003, 125, 10822; (b) El Oualid, F.; Burm, B. E. A.; Leroy, I. M.; Cohen, L. H.; van Boom, J. H.; van den Elst, H.; Overkleeft, H. S.; van der Marel, G. A.; Overhand, M. J. Med. Chem. 2004, 47, 3920.

- Chakraborty, T. K.; Srinivasu, P.; Tapadar, S.; Mohan, B. K. *Glycoconjugate J.* 2005, 22, 83.
- 7. Haubner, R.; Finsinger, D.; Kessler, H. Angew. Chem., Int. Ed. 1997, 36, 1374.
- 8. Burgess, K.; Feng, Y. Chemtracts: Org. Chem. 1997, 10, 1054.
- Venturi, F.; Venturi, C.; Liguori, F.; Cacciarini, M.; Montalbano, M.; Nativi, C. J. Org. Chem. 2004, 69, 6153.
- van den Bos, L. J.; Codée, J. D. C.; Van der Toorn, J. C.; Boltje, T. J.; van Boom, J. H.; Overkleeft, H. S.; van der Marel, G. A. Org. Lett. 2004, 6, 2165.
- Capozzi, G.; Giannini, S.; Menichetti, S.; Nativi, C.; Giolitti, A.; Patacchini, R.; Perrotta, E.; Altamura, M.; Maggi, C. A. Bioorg. Med. Chem. Lett. 2002, 12, 2263.
- Giannotti, D.; Perrotta, E.; Di Bugno, C.; Nannicini, R.; Harmat, N. J. S.; Giolitti, A.; Patacchini, R.; Renzetti, A. R.; Rotondaro, L.; Giuliani, S.; Altamura, M.; Maggi, C. A. J. Med. Chem. 2000, 43, 4041.
- 13. Quartara, L.; Altamura, M. Curr. Drug Targets 2006, 7, 975.
- 14. See Ref. 11 and references cited therein.
- 15. Siahaan, T. J.; Lutz, K. J. Pharm. Biomed. Anal. 1994, 12, 65.
- 16. Modeling studies were performed through the exploration of the conformational space with a random search approach at an empirical level. All the located conformations were re-optimized within the density functional approach at the B3LYP/6-31G(d) level. Then, the energy was recalculated using a continuum solvent model (PCM) to take into account the effect of water.
- 17. Lin, K.-C.; Castro, A. C. Curr. Opin. Chem. Biol. 1998, 2, 453.
- Belvisi, L.; Bernardi, A.; Colombo, M.; Manzoni, L.; Potenza, D.; Scolastico, C.; Giannini, G.; Marcellini, M.; Riccioni, T.; Castorina, M.; LoGiudice, P.; Pisano, M. Bioorg. Med. Chem. 2006, 14, 169.
- Owen, R. M.; Carlson, C. B.; Xu, J.; Mowery, P.; Fasella, E.; Kiessling, L. L. Chem BioChem 2007, 8, 68.
- Green, P. M.; Ludbrook, S. B.; Miller, D. D.; Horgan, C. M. T.; Barry, S. T. FEBS Lett. 2001, 503, 75.
- 21. The computational approach described for **15** was also applied to virtual cyclo(SAA**5**-Arg-Gly-Asp), that contains the RGD motif usually known to confer affinity for the $\alpha\nu\beta3$ integrin receptor when the tripeptide moiety assumes a kinked conformation. Calculations showed that the desired conformation is largely populated though this analog exhibits a certain degree of conformational freedom.